{"contentid": 488660, "importid": NaN, "name": "China NMPA accepts BLA for sacituzumab govitecan-hziy in breast cancer", "introduction": "The China National Medical Products Administration (NMPA) has accepted for review the Biologics License Application (BLA) for sacituzumab govitecan-hziy (SG), an investigational therapy for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease, submitted by Chinese biotech Everest Medicines.", "content": "<p>The China National Medical Products Administration (NMPA) has accepted for review the Biologics License Application (BLA) for sacituzumab govitecan-hziy (SG), an investigational therapy for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease, submitted by Chinese biotech Everest Medicines (HK: 1952).</p>\n<p>\"This aggressive and difficult-to-treat disease has historically had very limited treatment options, with overall survival remaining unchanged among patients for nearly two decades,\" said Yang Shi, chief medical officer for oncology at Everest Medicines. \"The outstanding and robust efficacy and safety results from the global Phase III ASCENT study demonstrate SG is an important potential new treatment option for people in China with metastatic TNBC,\" he noted.</p>\n<p><strong>Already approved in USA as Trodelvy</strong></p>\n<p>Licensed to US biotech major Gilead Sciences (Nasdaq: GILD), which uses the trade name Trodelvy, the US Food and Drug Administration previously granted accelerated approval to SG in April 2020 and full approval in April 2021 for adult patients with unresectable locally advanced or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease.</p>\n<p>The Ministry of Food and Drug Safety in South Korea has also recently granted Fast Track and Orphan Drug designations to SG for the treatment of metastatic TNBC. In addition, Everest announced in January 2021&nbsp;that it submitted a New Drug Application to the Health Sciences Authority of Singapore for SG for the treatment of patients with metastatic TNBC who have received at least two prior therapies for metastatic disease. That application is currently under review.&nbsp;</p>", "date": "2021-05-18 14:37:00", "meta_title": "China NMPA accepts BLA for sacituzumab govitecan-hziy in breast cancer", "meta_keywords": "China NMPA accepts BLA for\nEverest Medicines, Sacituzumab govitecan-hziy, Breast cancer, BLA, NMPA, Gilead Sciences, Trodelvy", "meta_description": "China NMPA accepts BLA for sacituzumab govitecan-hziy in breast cancer", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-18 14:36:27", "updated": "2021-05-18 14:44:53", "access": NaN, "url": "https://www.thepharmaletter.com/article/china-nmpa-accepts-bla-for-sacituzumab-govitecan-hziy-in-breast-cancer", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "everest-medicines.jpg", "image2id": "china_regulator_cnmpa_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Immuno-oncology", "topic_tag": "Asia Pacific, Focus On, Regulation", "geography_tag": "China, USA", "company_tag": "Everest Medicines, Gilead Sciences", "drug_tag": "sacituzumab govitecan, Trodelvy", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-18 14:37:00"}